Evidence map›Paper›PMID 32778904›Full record

ArticlePsychopharmacology2020

Altered baseline and amphetamine-mediated behavioral profiles in dopamine transporter Cre (DAT-Ires-Cre) mice compared to tyrosine hydroxylase Cre (TH-Cre) mice.

Muhammad O Chohan, Sari Esses, Julia Haft, Susanne E Ahmari, Jeremy Veenstra-VanderWeele

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Psychopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 32 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. A Drd1-cre mouse line with nucleus accumbens gene dysregulation exhibits blunted fentanyl seeking.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Muhammad O ChohanDepartment of Psychiatry, Columbia University Medical Center, New York, NY, 10032, USA.
Sari EssesNew York State Psychiatric Institute, 1051 Riverside Drive, Mail Unit 78, New York, NY, 10032, USA.
Julia HaftDepartment of Psychiatry, Columbia University Medical Center, New York, NY, 10032, USA.
Susanne E AhmariTranslational Neuroscience Program, Department of Psychiatry, University of Pittsburgh, 450 Technology Drive, Pittsburgh, PA, 15219, USA. ahmarise@upmc.edu.
Jeremy Veenstra-VanderWeeleDepartment of Psychiatry, Columbia University Medical Center, New York, NY, 10032, USA. jeremy.veenstra@nyspi.columbia.edu.ORCID http://orcid.org/0000-0002-6349-1076
Columbia University Irving Medical Center · USNew York State Psychiatric InstituteUniversity of Pittsburgh · US

Funding

Investigation of EAAT3 in OCD PathophysiologyR01MH114296 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI AHMARI, SUSANNE ELIZABETH, VEENSTRA-VANDERWEELE, JEREMY · 2017 to 2021
$2.7M
NIMH NIH HHS MH114296NIMH NIH HHS R01 MH114296
6 · The paper itself

Abstract

rationaleTransgenic mouse lines expressing Cre-recombinase under the regulation of either dopamine transporter (DAT) or tyrosine hydroxylase (TH) promoters are commonly used to study the dopamine (DA) system. While use of the TH promoter appears to have less liability to changes in native gene expression, transgene insertion in the DAT locus results in reduced DAT expression and function. This confound is sometimes overlooked in genetically targeted behavioral experiments.

objectivesWe sought to evaluate the suitability of DAT-Ires-Cre and TH-Cre transgenic lines for behavioral pharmacology experiments with DA agonists. We hypothesized that DAT-Ires-Cre expression would impact DAT-mediated behaviors, but no impact of TH-Cre expression would be observed.

methodsDAT-Ires-Cre and TH-Cre mice bred on mixed 129S6/C57BL/6 and pure C57BL/6 backgrounds were evaluated for novelty-induced, baseline, and amphetamine (AMPH)-induced locomotion, and for AMPH and D1 agonist (SKF-38393)-induced preservative behaviors.

resultsDAT-Ires-Cre mice on both mixed 129S6/C57BL/6 and pure C57BL/6 backgrounds displayed increased novelty-induced activity and decreased AMPH-induced locomotion, with mixed results for AMPH-induced stereotypy. TH-Cre mice on both backgrounds showed typical baseline activity and AMPH-induced stereotypy, with a difference in AMPH-induced locomotion observed only on the mixed background. Both transgenic lines displayed unaltered SKF-38393-induced grooming behavior.

conclusionsOur findings indicate that the DAT-Ires-Cre transgenic line may lead to confounds for experiments that are dependent on DAT expression. The TH-Cre transgenic line studied here may be a more useful option, depending on background strain, because of its lack of baseline and drug-induced phenotypes. These data highlight the importance of appropriate controls in studies employing transgenic mice.

Indexed as

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepineAmphetamineAnimalsDopamineDopamine AgonistsDopamine Plasma Membrane Transport ProteinsIntegrasesLocomotionMaleMiceMice, Inbred C57BLMice, TransgenicStereotyped BehaviorTyrosine 3-Monooxygenase2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepineAmphetamineCre recombinaseDopamineDopamine AgonistsDopamine Plasma Membrane Transport ProteinsIntegrasesTyrosine 3-Monooxygenase129S6/SvEvTacAmphetamineC57BL/6D1 agonistDopamine transporterInbred strainNovelty-induced locomotionStereotypic behaviorTransgenic miceTyrosine hydroxylase

Identifiers

PMID32778904
PMCPMC10120402
OpenAlexW3048907756

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.